Questions around this news
What does Soligenix’s Zacks research report cover?
The release says the Zacks Small-Cap Research report, issued March 12, reviews the company’s pipeline, financial positioning and anticipated clinical catalysts. It highlights HyBryte’s Phase 3 FLASH2 study and progress involving SGX945, also called dusquetide, for Behçet’s disease. The release describes several clinical readouts and milestones as anticipated during 2026.
What is CTCL?
CTCL stands for cutaneous T-cell lymphoma, a group of non-Hodgkin lymphomas in which certain T cells become cancerous and affect the skin. Symptoms and disease course can vary by subtype. The release identifies CTCL as the condition for which HyBryte is being evaluated, but does not provide further details about the disease or the study.
What does a Phase 3 clinical trial involve?
A Phase 3 trial generally tests a treatment in a larger group of people with the condition under study, often comparing it with a control or another treatment. Researchers assess whether the treatment works and monitor its safety. Results may contribute to a regulator’s review, but a Phase 3 designation alone does not establish that a treatment is effective or approved.
- Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026.
- At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL.
- Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease.
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors as Soligenix advances multiple programs toward key inflection points.
According to Zacks, Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. Central to this outlook is the company’s ongoing Phase 3 FLASH2 trial evaluating HyBryte(TM) (“SGX301”), SNGX’s lead therapeutic candidate for the treatment of…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- Soligenix
- Ticker
- NASDAQ: SNGX
Key figures
- FLASH2 study phase
- Phase 3
- Anticipated milestone year
- 2026
- Zacks report date
- March 12
Products and programs
SEC filings
Earlier from Soligenix
- Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
- Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
- Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
- Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
- Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
